Cégbemutató
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is a publicly listed on the Frankfurt Stock Exchange (Prime Standard) and London Stock Exchange (AIM) – B8F / ISIN: DE 0006046113. In February 2012 Biofrontera launched its prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through local partners. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this purpose Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. As cosmeceutical products Biofrontera markets Belixos® for the regenerative care of reddened and inflamed skin. Biofrontera developed a line of cosmeceutical products for damaged skin under the Belixos brand. The product portfolio includes the Belixos® cream, Belixos LIQUID®, Belixos® GEL and DayCare cream Belixos® PROTECT.
Igazgatóság & Felügyelőbizottság
CEO |
- |
Igazgatóság |
Ludwig Lutter |
Felügyelőbizottság |
Wilhelm K. T. Zours, Dr. Jörgen Tielmann, Dr. Heikki Lanckriet, Dr. Helge Lubenow, Karlheinz Schmelig, Prof. Dr. Franca Ruhwedel |
Cégadat
Név: |
Biofrontera AG |
Cím: |
Hemmelrather Weg 201,D-51377 Leverkusen |
Telefon: |
+49-214-87632-0 |
Fax: |
+49-214-87632-90 |
E-mail: |
info@biofrontera.com
|
Internet: |
www.biofrontera.com |
Ipar: |
Gyógyászat |
Szektor: |
Gyógyszeripar |
Alszektor: |
Gyógyszerek |
Pénzügyi év vége: |
12. 31. |
Közkézhányad: |
46,41% |
IPO dátum: |
- |
Befektetői kapcsolatok
Név: |
Anke zur Mühlen |
IR telefon: |
- |
IR Fax: |
- |
IR e-mail: |
ir@biofrontera.com
|